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Abstract
Aims This study aims to assess subclinical changes in functional and morphological myocardial magnetic resonance param-
eters very early into an anthracycline treatment, which may predict subsequent development of anthracycline-induced cardio-
myopathy (aCMP).
Methods and results Thirty sarcoma patients with planned anthracycline-based chemotherapy (360–400mg/m2 doxorubicin-
equivalent) were recruited. Median treatment time was 19.1 ± 2.1 weeks. Enrolled individuals received three cardiovascular
magnetic resonance studies (before treatment, 48 h after first anthracycline treatment, and upon completion of treatment).
Native T1 mapping (modified Look–Locker inversion recovery 5s(3s)3s), T2 mapping, and extracellular volume maps were
acquired in addition to a conventional cardiovascular magnetic resonance with steady-state free precession cine imaging at
1.5 T. Patients were given 0.2 mmol/kg gadoteridol for extracellular volume quantification and late gadolinium enhancement
imaging. Development of relevant aCMP was defined as drop of left ventricular ejection fraction (LVEF) by >10%. For analysis,
23 complete data sets were available. Nine patients developed aCMP with LVEF reduction >10% until end of chemotherapy.
Baseline LVEF was not different between patients with and without subsequent aCMP. When assessed 48 h after first dose of
antracyclines, patients with subsequent aCMP had significantly lower native myocardial T1 times compared with before therapy
(1002.0 ± 37.9 vs. 956.5 ± 29.2ms, P< 0.01) than patients who did not develop aCMP (990.9 ± 56.4 vs. 978.4 ± 57.4ms, P> 0.05).
Patients with aCMP had decreased left ventricularmass upon completion of therapy (86.9 ± 24.5 vs. 81.1 ± 22.3 g; P = 0.02), while
patients without aCMP did not show a change in left ventricular mass (81.8 ± 21.0 vs. 79.2 ± 18.1 g; P > 0.05). No patient
developed new myocardial scars or compact myocardial fibrosis under chemotherapy.
Conclusions Early decrease of T1 times 48 h after first treatment with anthracyclines can predict the development of sub-
sequent aCMP after completion of chemotherapy.
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Introduction
Anthracyclines are the mainstay of treatment in many malig-
nancies. Approximately 32% of all breast cancer patients,1
60% of elderly lymphoma patients, and most soft tissue sar-
coma patients receive anthracyclines during the course of
their oncological treatment.2
As outcomes of most cancer patients significantly improved
over the last decades, the number of cancer survivors has dras-
tically increased.3
This fortunate development leads to a progressive impor-
tance of long-term side effects of chemotherapy.
Anthracyclines are known to frequently have cardiotoxic
side effects. Heart failure due to anthracyclines has severe
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prognostic implications as it can lead to mortality rates worse
than that associated with many malignancies.4
The overall incidence of cardiotoxicity, defined as a reduc-
tion in left ventricular ejection fraction (LVEF) of >10%, has
been reported in up to 30% of patients receiving
anthracyclines.5
While the exact mechanism of cardiotoxicity has not been
fully understood yet, studies have shown that oxidative tissue
injury from free radicals, impaired protein synthesis, and al-
tered calcium handling in cardiomyocytes contribute to its
development.6,7
There is empirical evidence for the existence of risk factors
increasing the likelihood of cardiac dysfunction due to
anthracyclines, that is age, known cardiovascular disease,
dosage and bolus application.8
However, until now, there is no tool for prediction of
cardiotoxicity before or early in the treatment. Hence, clinical
guidelines and consensus statements of major cardiology and
oncology societies on prevention and treatment of
anthracycline-induced cardiomyopathy (aCMP) concentrate
on serial screening for LVEF reduction before, during, and af-
ter chemotherapy.9,10
Cardiovascular magnetic resonance (CMR) is a non-
invasive imaging technique that allows thorough myocardial
tissue differentiation. Myocardial T1 and T2 mapping are
promising techniques in this regard as they enable quantita-
tive assessment of diffuse myocardial tissue alteration
through a pixel-wise analysis approach.11,12
Several studies with animals and human cancer survivors
revealed that anthracycline therapy can induce diffuse myo-
cardial fibrosis several years after completion of treatment,
which can be assessed by T1 mapping.13,14
While myocardial fibrosis is well known to be associated
with increased risk for development of congestive heart fail-
ure and worse patient outcome, it can only be detected late
into or after completion of chemotherapy and, hence, has
no substantial preventive benefit for patients receiving
anthracyclines.15,16
Early preclinical detection of patients with aCMP could
lead to a benefit of earlier treatment, thus enabling patients
to receive full chemotherapy with lower risk for development
of aCMP.17
Until today, there is no single universally accepted
definition or categorization of cardiotoxicity by
anthracyclines. There are several types of aCMP that are
categorized according to timing of onset of cardiac
dysfunction into acute (days after start of chemotherapy),
early-onset (months after start of chemotherapy), and
late-onset aCMP (years after completion of chemotherapy).18
In this study, we focused on development of early-onset
aCMP.
We hypothesized that cardiotoxicity of anthracyclines af-
fects cardiac tissue morphology already very early into the
treatment and that these alterations may be detected by
CMR. Accordingly, the purpose of this study was to assess
the predictive value of parametric mapping techniques for
detection of acute effects of anthracyclines on cardiac tissue
at the beginning of treatment, which may lead to reduction in
LVEF after completion of treatment.
Methods
Study population
A total of 30 patients were prospectively recruited. All patients
had histologically confirmed soft tissue sarcoma and were
planned for anthracycline-based chemotherapy with a cumu-
lative doxorubicin-equivalent dose of 360–400 mg/m2. Exclu-
sion criteria were chronic renal failure (glomerular filtration
rate < 30 mL/m2), cardiac metastases, previous treatment
with anthracyclines, known incompatibility for gadolinium
contrast media, and contraindication for magnetic resonance
imaging. All enrolled individuals were approved by the local
ethical review board and gave written informed consent be-
fore participation.
Cardiovascular magnetic resonance protocol
All study participants underwent three CMR scans of 45 min
each on a 1.5 T Siemens AvantoFit® scanner (Siemens
Healthineers, Erlangen, Germany) with a 32 channel phased
array coil. The first CMR scan was performed within 48 h
before start of anthracycline treatment (baseline CMR), the
second scan 48 h after the first anthracycline treatment,
and the third scan 4 weeks after the last anthracycline
treatment (usually 5 to 6 months after begin of therapy).
Participants received 0.2 mmol/kg of gadoteridol contrast
agent (ProHance®, Bracco Diagnostics, Princeton, New Jersey)
during each scan. All imaging sequences were performed
according to previously published techniques. Left ventricular
(LV) and right ventricular (RV) volumetric and functional
parameters were assessed in long-axis and short-axis
steady-state free precession cine sequences. Cine imaging
parameters included field of view (FOV) 340 mm, voxel size
1.8 × 1.8 × 7 mm3, 3 mm gap, echo time (TE) 1.2 ms,
repetition time (TR) 33.4 ms, flip angle 74°, and bandwidth
930 Hz.
T1 mapping was performed using a modified Look–Locker
inversion recovery sequence in a mid-ventricular short-axis
slice before and 15 min after contrast administration. Se-
quence parameters include native T1: 5s(3s)3s with FOV
360mm, voxel size 1.6 × 1.6 × 7 mm3,TE 1ms, TR 339.4 ms, flip
angle 35°, and bandwidth 1063 Hz and post-contrast: 4s(1s)3s
(1s)2s with FOV 360 mm, voxel size 1.6 × 1.6 × 7 mm3, TE 1 ms,
TR 419.4 ms, flip angle 35°, and bandwidth 1063 Hz.
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Motion-corrected T2 mapping was performed using an
established T2 prepared steady-state free precession
technique (3 single-shot images with T2 preparation times
of 0/24/55 ms and voxel size of 1.6 × 1.6 × 6.0 mm).19
Late gadolinium enhancement (LGE) was used for focal
fibrosis imaging and performed in the same slice positions
as cine imaging using a gradient echo-based segmented
phase-sensitive inversion recovery sequence in single-slice,
single-breathhold fashion. LGE scan parameters: FOV
380 mm, voxel size 1.8 × 1.8 × 7 mm, no interslice gap,
TE 1 ms, TR 700 ms, flip angle 65°, and bandwidth
1184 Hz.
Image analysis
Experienced readers (F. M., S. F., L. Z., and A. S.) with at least
3 years of experience in cardiac MR analysis in a centre with
3.000 scans per year were blinded to clinical patient
information. All image analysis was performed using cvi42®
post-processing software version 4.2 (Circle Cardiovascular
Imaging Inc., Calgary, Canada). LV and RV size and function
as well as LV mass were assessed in short-axis cine images,
and atrial volumes were assessed monoplanar (right atrium)
or biplanar (left atrium) in long-axis cine four-chamber and
two-chamber views.
Epicardial and endocardial contours in a mid-ventricular
short-axis slice were traced for T1 and T2 mapping analyses
and a 5% safety margin was applied endocardial and epicar-
dial to minimize partial volume effects. Both T2 and T1 maps
were quantified as average global values in the analysed slice
as previously reported.19 Visual surveys were evaluated for
artefacts before quantification, and segments with relevant
artefacts were excluded from analysis (e.g. caused by suscep-
tibility, unintended motion effects, or incorrect motion
correction).
Relative and absolute extracellular volume (ECV) fraction
were calculated by means of native and post-contrast T1
values and haematocrit as previously established.12 Relative
ECV was reported as per cent of myocardial volume of the
corresponding short-axis plane, and absolute ECV in gram
extrapolated towards LV mass.
Visual evaluation of LGE images was performed by two
independent readers and included presence, location, and
transmurality of identified lesions. Differentiation of real
LGE lesions from artefacts was realized during image
acquisition by verification in two perpendicular slices or
altered readout direction.
Interobserver and intraobserver variability analysis was
performed on subsets of 10 subjects.
According to current guidelines, patients with LVEF drop of
>10% points were defined as patients with aCMP. All other
patients were defined non-aCMP patients for further
analysis.
Laboratory blood analysis
On the day of each CMR scan, venous blood samples were
obtained and immediately sent for laboratory analysis at
our central laboratory. High-sensitivity cardiac troponin T
concentrations were measured using the Elecsys® hsTNT
STAT assay (Roche Diagnostics, Mannheim, Germany). The
analytical limit of detection was 5 ng/L, and the 99th percen-
tile upper reference limit was 14 ng/L.
Plasma N terminal pro brain natriuretic peptide (NT-
proBNP) concentrations were measured using the Elecsys®
proBNP II assay (Roche Diagnostics). The analytical limit of
detection of NT-proBNP was 5 pg/mL.
Electrocardiography
A 12 lead electrocardiography (ECG) was obtained before each
CMR scan and assessed for pathological findings. In detail, pa-
tients were ranked positive if one of the following criteria was
newly present: no sinus rhythm, PQ interval of ≥200 ms, QRS
duration of ≥120 ms, and atrioventricular blockage, elevation,
or depression of ST interval > 0.1 mV. 30.
Statistical analysis
All measured values are shown as mean ± standard deviation.
Statistical analysis was performed using SPSS Statistics 22.0.0
(IBM, Armonk, NY, USA). Using Wilcoxon signed-rank test, sig-
nificant values were accepted by P < 0.05.
Univariate analysis for prediction of LVEF drop was per-
formed using two-sided t-test embedded into ANOVA analysis.
Correlation analyses were performed using the Spearman
rank correlation coefficients. To test for group-differences
of categorical variables χ2-test was applied.
For intraobserver and interobserver reproducibility, images
were analysed twice by blinded readers. The results were
evaluated by intraclass correlation coefficients.
Results
Patient characteristics
We initially recruited 30 patients. Seven individuals had to be
excluded because of early study abort because of individual
wish (n = 2) or termination of anthracycline chemotherapy
during the study (n = 5). Finally, we had 23 data sets for anal-
ysis. Mean age of study cohort was 58.7 ± 13.4 years; 12 pa-
tients (52%) were female. Baseline characteristics of study
cohort are summarized in Table 1. Patients received a mean
cumulative dose of doxorubicin-equivalent chemotherapy of
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342 ± 23 mg/m2 within a mean treatment time of
19.1 ± 2.1 weeks.
Left ventricular and right ventricular function
At the end of chemotherapy, nine patients had developed
LVEF reduction>10% as compared with baseline andwere de-
fined as aCMP patients for further analysis. See Figure 1A,B for
representative example. In this aCMP group mean, LVEF de-
creased from 63.5% ± 5.8% at baseline to 49.9% ± 5.0% after
chemotherapy (P < 0.01), whereas the remaining 14 non-
aCMP patients had no difference in LVEF until completion of
therapy (baseline: 59.2% ± 10.3%; after chemotherapy:
58.3 ± 7.8%; P = 0.47). Individual LVEF changes between
baseline and completion of chemotherapy are displayed in
Figure 2, and detailed results of anatomical and functional pa-
rameters of all CMR studies are illustrated in Table 2A. Nota-
bly, in aCMP patients, LV mass decreased from baseline
(86.9 ± 24.5 g) until completion of therapy (81.1 ± 22.3 g;
P = 0.02), while LV mass did not change in non-aCMP patients
over the course of chemotherapy (baseline: 81.8 ± 21.0 g; after
therapy: 79.2 ± 18.1 g).
As illustrated in Table 2A, at 48 h after the first treatment
with anthracyclines, non-aCMP patients showed an increase
in LVEF (59.2% ± 10.2% vs. 63.9% ± 7.9%, P = 0.02), LV end-
diastolic volume (165.1 ± 39.6 vs. 177.5 ± 36.2 mL,
P = 0.03), and RV ejection fraction (47.3% ± 59.% vs.
51.1% ± 6.2%, P < 0.01) as compared with baseline, while pa-
tients with subsequent aCMP did not. RV end-diastolic vol-
ume and LV mass did not change in either group after the
first dose of anthracyclines.
Myocardial tissue differentiation
In patients who developed aCMP, we observed a significant
decrease of native T1 times from 1002.0 ± 37.9 ms at baseline
to 956.5 ± 29.2 ms at 48 h after the first dose of anthracyclines
(P< 0.01). Patients without development of aCMP until com-
pletion of chemotherapy did not show a significant change in
Table 1 Patient characteristics
Patient characteristics
Age 58.7 ± 13.4 years
Gender 11 M/12 F
BMI 23.5 ± 3.4 kg/m2
Hypertension 11/23 (48%)
Diabetes 3/23 (13%)
CAD 1/23 (4%)
(Ex-) Smoker 5/23 (22%)
BMI, body mass index; CAD, coronary artery disease.
Figure 1 Representative anthracycline-induced cardiomyopathy imaging data. Steady-state free precession cine imaging captures in diastole and sys-
tole (A) before start of chemotherapy [baseline (left ventricular ejection fraction 65%)] and (B) after completion of chemotherapy (left ventricular ejec-
tion fraction 45%). (C) Native myocardial T1 maps of patient with anthracycline-induced cardiomyopathy before chemotherapy and 48 h after first dose
application. Displayed T1 times were measured as average global left ventricular times in each slice.
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native T1 at 48 h (990.9 ± 56.4 ms at baseline;
978.4 ± 57.4 ms at 48 h; P = 0.08). After completion of ther-
apy, native T1 times were not significantly different from
baseline values in either group. For details, see Figure 3, a
representative imaging example is displayed in Figure 1C. Re-
liability was excellent for both interobserver and
intraobserver evaluations (Spearman rank correlation for na-
tive T1 times rs = 0.90 with P = 0.01 and for T2 times rs = 0.91
with P = 0.01, intraclass correlation coefficient 0.96 for native
T1 and 0.98 for T2).
Extracellular volume analysis showed that relative and ab-
solute ECV values did not change significantly between base-
line and 48 h after first dose of anthracyclines in aCMP and
non-aCMP patients (Table 2B). Because of the loss in LV mass
over the course of chemotherapy, we observed an increase of
relative ECV after completion of chemotherapy in aCMP pa-
tients against baseline from 27.5% ± 2.7% to 29.8% ± 1.7%
(P = 0.04). However, this change was not verifiable in absolute
ECV values (23.4 ± 9.2 g at baseline vs. 26.8 ± 4.5 g after ther-
apy, P = 0.15; for details, see Table 2B).
Figure 2 Left ventricular ejection fraction (LVEF) development before and after chemotherapy. Red data points indicate anthracycline-induced cardio-
myopathy (aCMP) patients with LVEF drop of >10% during chemotherapy. Averages for aCMP and non-aCMP patients are displayed above.
Table 2 Quantitative magnetic resonance parameters. (A) Volumetric and functional assessment. (B) Myocardial tissue differentiation
parameters.
48 h after first dose After therapy
Before therapy P value P value
A
Non-aCMP LVEDV mL 165.1 ± 39.6 177.5 ± 36.2 0.03 164.7 ± 34.8 0.67
LVEF % 59.2 ± 10.2 63.9 ± 7.9 0.02 58.3 ± 7.8 0.47
RVEDV mL 185.7 ± 41.8 196.0 ± 43.0 0.06 184.6 ± 40.7 0.52
RVEF % 47.3 ± 5.9 51.1 ± 6.2 <0.01 47.2 ± 5.8 0.98
LVM g 81.8 ± 21.0 81.8 ± 20.1 0.92 79.2 ± 18.1 0.33
aCMP LVEDV mL 154.1 ± 32.2 164.3 ± 30.4 0.17 155.8 ± 25.0 0.86
LVEF % 63.5 ± 5.8 65.1 ± 4.9 0.34 49.9 ± 5.0 <0.01
RVEDV mL 171.2 ± 36.0 181.6 ± 40.7 0.11 156.9 ± 33.1 <0.01
RVEF % 51.7 ± 3.5 53.3 ± 3.7 0.34 44.2 ± 5.1 <0.01
LVM g 86.9 ± 24.5 85.5 ± 24.6 0.52 81.1 ± 22.3 0.02
B
Non-aCMP T2 ms 52.0 ± 3.5 52.9 ± 2.7 0.07 54.6 ± 3.2 0.08
Relative ECV % 26.4 ± 2.0 28.1 ± 2.7 0.12 29.4 ± 1.6 0.06
Absolute ECV g 21.0 ± 5.4 23.4 ± 5.8 0.20 23.7 ± 3.9 0.08
aCMP T2 ms 54.3 ± 2.8 55.3 ± 1.5 0.37 54.8 ± 2.9 0.73
Relative ECV % 27.5 ± 2.7 29.3 ± 2.7 0.16 29.8 ± 1.7 0.04
Absolute ECV g 23.4 ± 9.2 25.4 ± 8.6 0.33 26.8 ± 4.5 0.15
aCMP, anthracycline-induced cardiomyopathy; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVM,
left ventricular mass; RVEF, left ventricular ejection fraction; RVEDV, right ventricular end-diastolic volume.
P values indicate statistical significance towards baseline data (before therapy).
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On evaluation of T2 maps, we did not find focal lesions in
any patient at any time point. At baseline, average T2 times
were not different between patients with development of
subsequent aCMP (54.3 ± 2.8 ms) and non-aCMP patients
(52.0 ± 3.5 ms) (P = 0.11). Also, on follow-up at 48 h and after
completion of therapy, average T2 times did not significantly
change in either patient group. For details, see Table 2B.
LGE analysis revealed that three patients had myocardial
fibrosis at baseline CMR. Two of these three subjects were
in the non-aCMP group and had minor subendocardial scars
as well as known coronary artery disease. One individual
was in the aCMP group and had a small intramyocardial fibro-
sis inferolateral. None of the detected LGE lesions changed
on both follow-up CMR scans. No patient developed new
LGE lesions over the course of this study.
Laboratory results
High-sensitive troponin T and NT-proBNP blood analysis are
displayed in Table 3. There was no significant difference in tro-
ponin T levels at baseline between aCMP (11.4 ± 11.2 ng/L) and
non-aCMP patients (8.1 ± 6.5 ng/L) and no significant change at
48 h after first anthracycline treatment (aCMP: 11.4 ± 7.2 ng/L;
non-aCMP: 8.6 ± 7.0 ng/L). However, upon completion of study,
we observed an increase of troponin T levels against baseline in
both patient groups (aCMP: 17.7 ± 8.5 ng/L – P = 0.04; non-
aCMP: 23.3 ± 25.3 ng/L – P< 0.01). NT-proBNPwas neither dif-
ferent between aCMP and non-aCMP patients at any time
point nor did we see a statistically significant increase at 48 h
or upon completion of chemotherapy (Table 3). Glomerular fil-
tration rates did not significantly change in aCMP (baseline:
87.8 ± 14.1 mL/min/1.73 m2; at 48 h: 91.1 ± 16.5 mL/min/
1.73 m2; after chemotherapy: 90.8 ± 13.6 mL/min/1.73 m2,
P > 0.05) and non-aCMP patients (baseline: 88.1 ± 18.0 mL/
min/1.73 m2; at 48 h: 91.8 ± 19.1 mL/min/1.73 m2; after che-
motherapy: 93.9 ± 20.3 mL/min/1.73 m2, P > 0.05) over the
course of the study.
Conduction abnormalities
We found ECG abnormalities only in three patients, two of
which were in the aCMP group. One aCMP patient had first
Figure 3 Native T1 mapping. Grey columns represent patients without development of anthracycline-induced cardiomyopathy (aCMP), and red col-
umns represent aCMP patients. P values indicate statistical significance towards baseline data (before therapy).
Table 3 Laboratory blood test assessment
Before therapy
48 hr after first dose After therapy
P value P value
Non-aCMP High-sensitive troponin T ng/L 8.1 ± 6.5 8.6 ± 7.0 0.71 23.3 ± 25.3 <0.01
NT-proBNP pg/mL 169.9 ± 160.8 175.0 ± 163.5 0.33 203.0 ± 208.4 0.19
aCMP High-sensitive troponin T ng/L 11.4 ± 11.2 11.4 ± 7.2 0.65 17.7 ± 8.5 0.02
NT-proBNP pg/mL 160.7 ± 209.0 169.4 ± 181.2 0.55 265.0 ± 304.7 0.30
aCMP, anthracycline-induced cardiomyopathy; NT-proBNP, N terminal pro brain natriuretic peptide.
P values indicate statistical significance towards baseline data (before therapy).
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degree atrioventricular blockage after completion of therapy,
which was not present at baseline. In the other aCMP pa-
tient, we detected atrial fibrillation after chemotherapy but
normal sinus rhythm at baseline and at 48 h after therapy
start. One non-aCMP patient had complete LV branch block
at baseline, which was persistent on follow-up ECGs.
Discussion
In this study, we were able to detect several myocardial tis-
sue changes predicting an early-onset cardiomyopathy be-
cause of anthracyclines. Firstly, 30% of recruited patients
showed a decrease in LVEF of more than 10% over the course
of an anthracycline-based chemotherapy, which was defined
as development of aCMP. Secondly, all patients who develop
aCMP (30% of recruited patients) had decreased LV mass
upon completion of therapy, while patients without aCMP
did not show a change in LV mass. Thirdly, a decrease of na-
tive myocardial T1 time within 48 h after the first dose of
anthracyclines was associated with subsequent development
of aCMP. This acute decrease in native T1 time resolved in all
aCMP patients until completion of therapy. Finally, myocar-
dial T2 mapping, absolute ECV values, and blood biomarkers
did not qualify to discriminate between patients with and
without development of aCMP in this study.
The prevalence of aCMP has been shown to be 3% to 48%
depending on several variables.5,20,21 Besides the cumulative
dose of anthracyclines administered being one major risk fac-
tor for aCMP, there is evidence that the type of imaging mo-
dality for LVEF evaluation impacts detection rates for aCMP.
CMR is widely accepted as the reference method for mea-
surement of LV volumes and LVEF because of best reproduc-
ibility among non-invasive imaging techniques.22,23
In several studies, CMR was shown to be superior to echo-
cardiography in detection of LVEF decline under
anthracycline therapy, that is revealing an LVEF drop to
<50% in 26% of all patients within 6 months of therapy using
CMR, which is in line with our results.23,24
Our finding that patients with aCMP show a reduction of LV
mass over the course of chemotherapy is in line with previous
limited data on anthracyclines as well as trastuzumab therapy.25
Lipshultz et al. performed serial echocardiography on chil-
dren receiving anthracyclines. They found that LV decreased
over time under anthracycline therapy and that the reduction
in LV mass was inversely related to cumulative dose of
anthracyclines.26
Because patients in this study received similar cumulative
dose of anthracyclines independent of development of aCMP,
the dosing factor should play a minor role in our cohort.
Myocardial atrophy and cachexia are known to be inde-
pendent predictors for mortality in cancer patients.27 The de-
crease of LV mass in patients with aCMP in this study shows
that myocardial atrophy may also serve as phenotypic
criterion for aCMP. However, it is difficult to say if LV atrophy
is cause or consequence of aCMP.
Myocardial T1 and T2 mapping, including the derived ECV,
are recognized as potential biomarkers of chemotherapy
cardiotoxicity that may have the ability to detect myocardial
tissue damage earlier than conventional functional metrics.
Several CMR studies with cancer survivors have investigated
changes in native myocardial T1 and T2 times and found that
anthracyclines can cause an increase of native T1 times and
ECV because of development of diffuse myocardial fibrosis
years after completion of treatment.14,28
Hence, there clearly is a long-term myocardial remodelling
effect because of anthracyclines, which increases risk for car-
diovascular disease.
In this study, we demonstrated evidence that an early de-
crease of native myocardial T1 time after the first administra-
tion of anthracyclines is linked to subsequent development of
aCMP, allowing for very early identification of patients at
high risk for aCMP.
The pathophysiologic mechanism behind this decrease in
native T1, however, remains unclear. There is a lack of previ-
ous histologic or imaging data at this early timing of myocar-
dial tissue assessment after drug administration.
In an earlier study from our group, we reported that
changes in early myocardial enhancement after gadolinium
administration can predict LVEF drop after 28 days in patients
treated with anthracyclines.29 However, there was no longer
follow-up of patients.
One hypothesis includes the involvement of radical oxygen
species, which are known to play a key role in anthracycline-
mediated cardiotoxicity and which affect mitochondrial func-
tion and increase lipid peroxidation.30
Native T1 time is increased in case of myocardial oedema
or inflammation and decreased by iron overload such as in
haemochromatosis or in case of lipid deposition as in Fabry
disease.31
While it is unlikely that a temporary myocardial iron over-
load is triggered by anthracyclines, they may lead to an in-
crease of intracellular lipid contents affecting native
myocardial T1 times.
Other acute anthracycline-meditated biochemical abnor-
malities in cardiomyocytes may also play a role in the ob-
served decrease of native T1 times.
Our observation that T1 times normalize again upon com-
pletion of therapy further strengthen the possibility that
acute toxic effects are meditating the early native T1 de-
crease rather than permanent structural changes such as in-
terstitial fibrosis.
This is supported by our finding that absolute ECV values
did not change in our study population—neither acutely after
the first administration of anthracyclines nor upon comple-
tion of therapy. Other groups have reported that there is in-
crease in relative ECV because of anthracyclines, which may
occur even years after therapy.14
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In our opinion, there certainly is a degree of increased fi-
brosis attributing to increased relative ECV in the long term.
However, the reduction of LV mass during and after cancer
therapy due to weight loss and systemic atrophy may also af-
fect relative ECV values, while absolute ECV values remain
largely unaffected as reported in this study.
In our study, we did not find significant changes in myocar-
dial T2 time under and after chemotherapy, which other
groups have reported. Farhad et al. found increased myocar-
dial T2 times in mice treated with anthracyclines at 5 weeks
after beginning of anthracycline treatment, which resolves
upon a 20 week follow-up.32
In our opinion, timing of imaging is crucial for interpreta-
tion of results. Cardiotoxicity of anthracyclines may not trans-
late into a single long-term pathophysiolic mechanism but
may rather consist of several phases. Acute toxic effects
may lead to early native T1 changes as observed in this study,
while chronic myocardial remodelling due to anthracyclines
may lead to increased native T1 times and elevated ECV be-
cause of diffuse interstitial fibrosis in cancer survivors.
Besides imaging parameters, blood biomarkers have been
shown to be altered in patients with aCMP.33,34
In our study, we observed significant elevations of high-
sensitive troponin T. However, these changes occurred inde-
pendent of development of aCMP. Troponin T is a sensitive
biomarker for myocardial cell death and may therefore be el-
evated even in patients with minor myocardial damage,
which does not lead to systolic heart failure.
NT-proBNP is well established as a biomarker for heart fail-
ure, thus maybe elevated in patients developing aCMP. How-
ever, in contrast to troponin T, we did not see significant
changes of NT-proBNP levels in patients with or without
aCMP. This is in line with findings from other groups.35,36
In conclusion, native myocardial T1 mapping may repre-
sent a suitable tool for aCMP risk stratification very early into
the treatment. In contrast to other imaging parameters, it can
help to predict aCMP development before functional cardiac
impairment occurs. Larger, interventional studies are needed
to investigate if preventive measures—such as primary aCMP
prevention with beta-blockers or angiotensin-converting
enzyme inhibitors—inhibit the early decrease of native T1
times after anthracycline treatment.
Limitations
In this study, we observed patients only until completion of
therapy; however, long-term effects of anthracyclines can
also develop years after completion of treatment. Studies
with longer follow-up may help to discriminate between pa-
tients with early-onset and late-onset aCMP.
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